The development of therapeutics has been relatively neglected in the global response to COVID-19 – and with the few treatment innovations available principally in high-income countries, we risk repeating history and replicating the vaccine inequality that has become a defining characteristic of this global pandemic.
This DNDi Policy Report urges the international community to learn the positive lessons and avoid repeating mistakes that would hinder innovation of and access to COVID-19 therapeutics, offering a series of recommendations for immediate course-correction based on our experience as an R&D organization. These include increasing attention on the need for therapeutics; transforming the governance structure of the Access to COVID-19 Tools Accelerator (ACT-A) to provide equal representation from low- and middle-income countries; and securing policies such as a temporary waiver on intellectual property to ensure transfer of technology to ensure access for all.
Watch our webinar:
